EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined Bowel Urgency, Clinical Outcomes, and Quality of Life Improvement in Mirikizumab-Treated Ulcerative Colitis: A Step Toward Comprehensive Disease Management

Stefan Schreiber iD, Jianmin Wu iD, Yajie Duan iD, Anthony Keohane, Seyedehsan Navabi iD, David T Rubin iD

Crohn's & Colitis 360 · 10.06.2026

DOI: 10.1093/crocol/otag051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 10.06.2026. Verfasst von Stefan Schreiber und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With increasing emphasis on patient-centric care, treatment goals for ulcerative colitis (UC) now include bowel urgency (BU), stool frequency, and rectal bleeding (RB) resolution, enhancement of overall well-being, and endoscopic remission (ER). This analysis evaluated the impact of adding BU improvement to clinical remission, defined by the modified Mayo score (RB, stool frequency, ER), on quality-of-life assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ). The effect of mirikizumab on achieving combined clinical, BU, and IBDQ remissions was also evaluated in the LUCENT-1 and -2 trials.

Methods

In LUCENT-1, patients were randomized 3:1 (mirikizumab to placebo) every 4 weeks. At week 12, mirikizumab responders were re-randomized 2:1 (mirikizumab to placebo) for 40 additional weeks in LUCENT-2. BU improvement was assessed using a clinically meaningful improvement (Urgency Numeric Rating Scale (UNRS) ≥ 3-point change) and BU remission (UNRS = 0 or 1). The impact of mirikizumab on achieving single and combined outcomes was determined at weeks 12 and 52.

Results

Significant IBDQ improvement at both timepoints (P ≤ .01) was observed by achieving both BU improvement and clinical remission versus clinical remission alone. Significantly more mirikizumab-treated patients achieved single and combined endpoints of clinical, BU, and IBDQ remissions versus placebo (P ≤ .05).

Conclusions

The addition of BU improvement in patients who had already attained clinical response or remission is associated with greater quality of life. Mirikizumab delivered comprehensive benefit for patients with UC by relieving BU symptoms, resolving endoscopic inflammation, and enhancing overall well-being concurrently.

Schlagwörter

Stichwörter der Autor:innen

IBDQbowel urgencycombined clinical and patient-reported outcomesmirikizumabulcerative colitis

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Eli Lilly and Company, Indianapolis, IN, United States.
  • HaaPACS GmbH, StatisticsSchriesheim, Germany, Europe.
  • United Medical Doctors, Murrieta, CA, United States.
  • University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States.

ORCID-Profile: Stefan Schreiber, Jianmin Wu, Yajie Duan, Seyedehsan Navabi, David T Rubin

Zitieren

APA

Schreiber, S., Wu, J., Duan, Y., Keohane, A., Navabi, S., & Rubin, D. T. (2026). Combined Bowel Urgency, Clinical Outcomes, and Quality of Life Improvement in Mirikizumab-Treated Ulcerative Colitis: A Step Toward Comprehensive Disease Management. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag051

Vancouver

Schreiber S, Wu J, Duan Y, Keohane A, Navabi S, Rubin DT. Combined Bowel Urgency, Clinical Outcomes, and Quality of Life Improvement in Mirikizumab-Treated Ulcerative Colitis: A Step Toward Comprehensive Disease Management. Crohn's & Colitis 360. 2026. doi:10.1093/crocol/otag051

BibTeX
@article{Schreiber2026,
  author = {Schreiber, Stefan and Wu, Jianmin and Duan, Yajie and Keohane, Anthony and Navabi, Seyedehsan and Rubin, David T},
  title = {Combined Bowel Urgency, Clinical Outcomes, and Quality of Life Improvement in Mirikizumab-Treated Ulcerative Colitis: A Step Toward Comprehensive Disease Management},
  journal = {Crohn's & Colitis 360},
  year = {2026},
  doi = {10.1093/crocol/otag051}
}
Kostenlos starten →